Patents by Inventor Daniel Johannes KOWALEWSKI

Daniel Johannes KOWALEWSKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS
    Publication number: 20220356208
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: July 8, 2022
    Publication date: November 10, 2022
    Inventors: Juliane Sarah WALZ, Daniel Johannes KOWALEWSKI, Markus LOEFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN
  • IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS
    Publication number: 20220348630
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: May 13, 2022
    Publication date: November 3, 2022
    Inventors: Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH, Gisela SCHIMMACK, Michael ROEMER
  • PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS
    Publication number: 20220332760
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 24, 2022
    Publication date: October 20, 2022
    Inventors: Juliane Sarah WALZ, Daniel Johannes KOWALEWSKI, Markus LOEFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN
  • IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS
    Publication number: 20220324941
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 3, 2022
    Publication date: October 13, 2022
    Inventors: Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH, Gisela SCHIMMACK, Michael ROEMER
  • IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS
    Publication number: 20220306721
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: May 27, 2022
    Publication date: September 29, 2022
    Inventors: Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH, Gisela SCHIMMACK, Michael ROEMER
  • IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS
    Publication number: 20220289817
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: May 27, 2022
    Publication date: September 15, 2022
    Inventors: Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH, Gisela SCHIMMACK, Michael ROEMER
  • IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS
    Publication number: 20220289816
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: May 27, 2022
    Publication date: September 15, 2022
    Inventors: Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH, Gisela SCHIMMACK, Michael ROEMER
  • METHOD FOR THE ABSOLUTE QUANTIFICATION OF MHC MOLECULES
    Publication number: 20220283176
    Abstract: The present invention relates to a method for the absolute quantification of one or more MHC molecules in a test sample comprising at least one cell, the method comprising at least the steps of: homogenizing the sample, adding an internal standard to the sample, digesting the homogenized sample with a protease, before or after addition of the internal standard, purifying the sample obtained by the digestion, subjecting the digested sample to a step of chromatography and/or spectrometry analysis, and quantifying the one or more MHC molecules in the test sample Also, the invention relates to method of determining the cell count in a sample. (FIG. 1).
    Type: Application
    Filed: March 3, 2022
    Publication date: September 8, 2022
    Inventors: Christoph SCHRAEDER, Heiko SCHUSTER, Lena Katharina FREUDENMANN, Lida ROSTOCK, Linus BACKERT, Michael ROEMER, Daniel Johannes KOWALEWSKI
  • Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods
    Patent number: 11433099
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: September 6, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Gisela Schimmack, Annika Sonntag, Heiko Schuster, Daniel Johannes Kowalewski, Michael Roemer, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Harpreet Singh
  • IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS
    Publication number: 20220267408
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 25, 2022
    Inventors: Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH, Gisela SCHIMMACK, Michael ROEMER
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20220226376
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 14, 2022
    Publication date: July 21, 2022
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
    Patent number: 11376281
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: July 5, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
  • Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
    Patent number: 11369636
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: June 28, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
  • Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
    Patent number: 11357797
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: June 14, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
  • PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS
    Publication number: 20220118016
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 23, 2021
    Publication date: April 21, 2022
    Inventors: Juliane Sarah WALZ, Daniel Johannes KOWALEWSKI, Markus LOEFFLER, Moreno DI MARCO, Nico TRAUTWEIN, Annika NELDE, Stefan STEVANOVIC, Hans-Georg RAMMENSEE, Sebastian HAEN
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20220111022
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 29, 2021
    Publication date: April 14, 2022
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20220098269
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 29, 2021
    Publication date: March 31, 2022
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR
  • A*03 restricted peptides for use in immunotherapy against cancers and related methods
    Patent number: 11246917
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: February 15, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Colette Song, Linus Backert, Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
  • IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS
    Publication number: 20220009982
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: September 14, 2021
    Publication date: January 13, 2022
    Inventors: Heiko SCHUSTER, Annika SONNTAG, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH, Colette SONG
  • IMMUNOTHERAPY WITH B*08 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS
    Publication number: 20220008471
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: September 24, 2021
    Publication date: January 13, 2022
    Inventors: Gisela SCHIMMACK, Annika SONNTAG, Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Michael ROEMER, Jens FRITSCHE, Oliver SCHOOR, Toni WEINSCHENK, Harpreet SINGH